Scynexis, Inc.   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Durham NC United States (1999)

Organization Overview

First Clinical Trial
2007
NCT01290965
First Marketed Drug
2021
Ibrexafungerp (Brexafemme)
First NDA Approval
2021
Ibrexafungerp (Brexafemme)
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

SCYNEXIS | Scynexis, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Aspergillosis (Phase 3)

Aspergillosis, Allergic Bronchopulmonary (Phase 3)

Blastomycosis (Phase 3)

Candidemia (Phase 3)

Candidiasis (Phase 3)

Candidiasis, Chronic Mucocutaneous (Phase 3)

Candidiasis, Invasive (Phase 3)

Candidiasis, Vulvovaginal (Phase 3)

Coccidioidomycosis (Phase 3)

Coccidiosis (Phase 3)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis C (Phase 2)

Hepatitis C, Chronic (Phase 1)

Hepatitis, Chronic (Phase 1)

Histoplasmosis (Phase 3)

Infections (Phase 2)

Invasive Pulmonary Aspergillosis (Phase 3)

Mycoses (Phase 3)

Pulmonary Aspergillosis (Phase 3)

Vulvovaginitis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 17
  • # of Trial APIs: 9